ARK Next Generation Technology ETF news

Part of Ark's portfolio strategy focused on disruptive technology and fintech, benefiting from the same contrarian investment thesis and exposure to Tesla's autonomous vehicle potential.

Received SpaceX allocation (28,763 shares worth $56 million), reflecting SpaceX's role in satellite communications and internet connectivity through Starlink.

Actively buying Meta and other AI-focused companies, positioning for long-term growth in disruptive technology sectors including AI, robotics, and space exploration.

Similarly purchasing Cerebras shares (4,130 shares Friday plus 19,980 shares Wednesday), showing strategic positioning in AI growth with 1.6% weighting in the fund.

Directly purchased 325,562 SpaceX shares, making SpaceX a 2.6% holding in this fund.

The ETF showed minimal movement (-0.13%) and is mentioned only as a related holding, with no specific news or catalyst driving sentiment.

Cerebras was added to this ETF by Cathie Wood, indicating the company fits Ark's strategy for next-generation technology investments.

Cathie Wood's active management in adding Cerebras reflects confidence in identifying emerging technology leaders.

Similarly added Cerebras shares with modest weighting (1.1%); represents continued interest but not a major portfolio position.

Offers exposure to Cerebras and other AI/cloud infrastructure companies; holds positions in Advanced Micro Devices and Nvidia; recommended as alternative for investors seeking greater Cerebras exposure with diversification

ETF declined 2.88% on Tuesday due to broader market sell-off and exposure to growth stocks like Tesla affected by inflation concerns.

Similar benefits to ARKK with daily tradability and low fees, offering 3% OpenAI exposure within a broader AI/tech portfolio.

The ETF declined 3.80% on the trading day. As a technology-focused fund likely holding Roku, the stock's decline and broader tech sector weakness contributed to this underperformance.

ETF gained 0.72% on the day. CoreWeave carries significant weight in this fund, but the modest gain suggests balanced performance despite CRWV's decline.